Rep. Gilbert Cisneros Purchases Shares in BridgeBio Pharma
Cisneros disclosed a purchase of BridgeBio Pharma shares valued between $1,001 and $15,000.
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| BridgeBio Pharma, Inc. ($BBIO) | Buy | May 11, 2026 | $1,001 - $15,000 |
Key Points
- Rep. Gilbert Cisneros bought BridgeBio Pharma shares, valued between $1,001 and $15,000, as disclosed on June 9, 2026.
- BridgeBio Pharma, trading at $67.14, has a market cap of $13.08 billion and a forward P/E of 134.9.
- Insiders and analysts show active interest, with CEO Neil Kumar selling shares and analysts maintaining 'buy' ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 9, 2026, Rep. Gilbert Cisneros disclosed a purchase of BridgeBio Pharma, Inc. shares, valued between $1,001 and $15,000. This transaction was reported as part of the STOCK Act requirements, which mandate the disclosure of stock trades by members of Congress.
Gilbert Cisneros vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
BridgeBio Pharma, Inc. Stock Down 12.5%
Shares of NasdaqGS:BBIO traded at $67.14 recently. BridgeBio Pharma, Inc. is a biotechnology company based in Palo Alto, California, with a market capitalization of about $13.08 billion. The company has a forward P/E ratio of 134.9 and a beta of 0.975, indicating moderate volatility. Over the past year, the stock has ranged from $38.58 to $84.94, with recent moving averages of $70.28 (50-day) and $67.14 (200-day).
$BBIO stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at BridgeBio Pharma, Inc.
Insider activity at BridgeBio Pharma has been notable. CEO Neil Kumar sold 40,000 shares at an average price of $67.88 on June 5, 2026, as part of a planned sale. Earlier, on May 16, 2026, Kumar bought 71,215 shares, showing active involvement in the company's stock. Additionally, President and CFO Thomas Trimarchi sold 22,781 shares at $66.13 on May 16, 2026.
Analysts Set New Price Targets
BridgeBio Pharma has caught the attention of analysts. On June 3, 2026, Canaccord Genuity initiated coverage with a 'buy' rating and a $104 price target. HC Wainwright & Co. maintained a 'buy' rating with a $110 target on May 11. The consensus among 23 analysts is a 'strong buy,' with an average price target of $102.71.
About BridgeBio Pharma
BridgeBio Pharma, Inc., founded in 2015, is a biopharmaceutical company focused on developing treatments for genetic diseases. The company, headquartered in Palo Alto, California, is led by CEO Dr. Neil Kumar and employs 834 people. BridgeBio develops a range of medicines, including those for cardiomyopathy, molybdenum cofactor deficiency, and genetic bone disorders.
Bottom Line
Rep. Gilbert Cisneros's purchase of BridgeBio Pharma shares adds to the interest in the company from both insiders and analysts. While the 13F filings are backward-looking, this disclosure highlights ongoing interest in the biotech sector. Investors often track such moves for insights into potential trends and market sentiment.
Get BridgeBio Pharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.